For help on how to get the results you want, see our search tips.
549 results
Medicine
Orphan designations Remove Orphan designations filter
Paediatric investigation plans Remove Paediatric investigation plans filter
PIP decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) Remove P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter
RPM: decision refers to a refusal on the application for modification of an agreed PIP Remove RPM: decision refers to a refusal on the application for modification of an agreed PIP filter
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale and Artemisia vulgaris
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000851-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 22/12/2010, Last updated: 24/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): misoprostol
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001601-PIP01-13, Route(s) of administration: Oral use, Sublingual use, Vaginal use, Pharmaceutical form(s): Tablet
Decision date: 05/06/2015, Last updated: 02/09/2015, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Risperidone
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Psychiatry
PIP number: EMEA-001034-PIP01-10, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 06/07/2011, Last updated: 09/08/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Alnus glutinosa
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000906-PIP01-10, Route(s) of administration: Sublingual use, Pharmaceutical form(s): Oromucosal drops
Decision date: 03/12/2010, Last updated: 11/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001430-PIP01-13, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 02/04/2014, Last updated: 07/12/2016, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Kineret, anakinra
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Immunology-Rheumatology-Transplantation
PIP number: EMEA-001212-PIP01-11, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 28/03/2012, Last updated: 19/04/2012, Compliance check: V, 12/12/2014 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant human granulocyte colony stimulating factor coupled with recombinant human albumin fusion protein
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001042-PIP02-11, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 20/12/2011, Last updated: 19/01/2012, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Gevokizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Ophthalmology
PIP number: EMEA-001487-PIP01-13, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 13/06/2014, Last updated: 02/10/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): grass pollen, cereal pollen
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000964-PIP01-10, Route(s) of administration: Sublingual use, Pharmaceutical form(s): Oral solution
Decision date: 22/12/2010, Last updated: 25/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): rye pollen
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000943-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 22/12/2010, Last updated: 25/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Zometa, zoledronic acid
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000024-PIP01-07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Powder and solvent for solution for infusion, Concentrate for solution for infusion
Decision date: 24/06/2008, Last updated: 21/07/2008, Compliance check: V, 12/12/2008 -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Emicizumab
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Haematology-Hemostaseology
PIP number: EMEA-001839-PIP01-15, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 15/07/2016, Last updated: 22/09/2016, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): exenatide
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001755-PIP01-15, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Implant
Decision date: 18/03/2016, Last updated: 25/04/2016, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): grass pollen
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000954-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 22/12/2010, Last updated: 25/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dermatophagoides farinae, Dermatophagoides pteronyssinus
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000866-PIP01-10, Route(s) of administration: Oral use, Pharmaceutical form(s): Oral solution
Decision date: 03/01/2011, Last updated: 07/02/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,- 14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]- oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyldimethyl-phosphinate (MK-8669, or AP23573)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Oncology
PIP number: P/2/2010, Route(s) of administration: Oral use, Intravenous use, Pharmaceutical form(s): Gastro-resistant tablet, Age-appropriate dosage form, other, Age-appropriate dosage form for parenteral use
Decision date: 25/01/2010, Last updated: 25/02/2010, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Evacetrapib
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-001180-PIP01-11, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral solid dosage form
Decision date: 05/07/2013, Last updated: 22/10/2015, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): mugwort pollen, grass pollen
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000929-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 22/12/2010, Last updated: 24/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): nicotinic acid, laropiprant
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000251-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Prolonged-release tablet
Decision date: 23/06/2008, Last updated: 21/07/2008, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Entospletinib
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Oncology
PIP number: EMEA-002058-PIP01-16, Route(s) of administration: Oral use, Gastric use, Pharmaceutical form(s): Film-coated tablet, Age-appropriate oral solid dosage form
Decision date: 04/10/2017, Last updated: 12/02/2018, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Chimeric monoclonal anti-Shiga toxin antibodies cαStx1 and cαStx2
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Infectious diseases
PIP number: EMEA-001134-PIP01-11, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for injection
Decision date: 20/12/2011, Last updated: 19/01/2012, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dermatophagoides pteronyssinus, Dermatophagoides farinae
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000934-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 22/12/2010, Last updated: 26/01/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Taspoglutide
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Endocrinology, -gynacology-fertility-metabolism
PIP number: EMEA-000665-PIP01-09, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 07/05/2010, Last updated: 20/04/2011, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000841-PIP01-10, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Suspension for injection
Decision date: 26/11/2010, Last updated: 21/12/2010, Compliance check: X -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Proteinase, metallo- (synthetic nociceptin receptor-binding) 1290102-81-6 (AGN214868)
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pain
PIP number: EMEA-001200-PIP01-11, Route(s) of administration: Intradermal use, Intramuscular use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 26/02/2013, Last updated: 23/04/2013, Compliance check: X